/
We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted m…
$3.10
$0.03 (-0.96%)
Live · 05:19 PM
The business is unprofitable at the operating level (-4498.06% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 55.3% YoY with margins expanding 2289.3pp.
Negative free cash flow of -$167M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$5M
▲ +55.3% YoY
Net Income (TTM)
-$198M
▼ -2.7% YoY
Op. Margin
-4498.06%
▲ +2289.3pp YoY
ROIC
-73.44%
▲ +17.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$159M
▼ -28.4% YoY
Op. Cash Flow (TTM)
-$156M
▼ -32.3% YoY
Net Debt
-$21M
Net Cash Position
Cash & Equiv.
$135M
5Y CAGR: -2.3%
Continue Research
Prime Medicine (PRME)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Prime Medicine scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Prime Medicine scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -4,498.1% operating margin and a -73.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh PRME's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.